 

I. The Complaint

3. On or about November 23, 2015, the Facility notified the Board through
two Mandated 10-Day Reports (the Reports") that: (a) effective November 17, 201 5,
the Respondent took a leave of absence from duty following an emergency room visit to
an outside hospital for an opioid overdose; and (b) on November 23, 2015, the
Respondent submitted his resignation from the fellowship program, effective December
9, 2015.
Hl. Board Investigative allegations

4. The Board initiated an investigation of the Respondent based on the
above Reports. The Board's investigation determined that the Respondent, while
enrolled in a fellowship program at the Facility, engaged in immoral or unprofessional
conduct in the practice of medicine and/or practiced medicine while using a narcotic or
controlled substance or other drug in excess of therapeutic amounts or without valid
medical indication. The Board's investigation determined that while enrolled as an UMP
at the Facility, the Respondent was hospitalized on two separate occasions for opioid
overdoses. On both occasions, Emergency Medical Services ("EMS") personnel
responded to motels in Baltimore County (both of which were in close geographic
proximity) where they found the Respondent in an unconscious state. On both
occasions, EMS personnel administered naloxone? to the Respondent and transported
him to the emergency department ("ED") of a nearby hospital (the “Hospital") for
emergency treatment, where he was diagnosed with opiate overdoses. During these
incidents, the Respondent admitted to using illicit substances, including but not limited

° Naloxone, sold under the brand name Narcan, is a prescription medication that blocks the effects of
opioids and reverses opioid overdoses. It is indicated for the emergency treatment of opioid overdose.

3
